Fermín Sánchez-Guijo Martín-rekin lankidetzan egindako argitalpenak (10)

2022

  1. Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome

    Frontiers in Immunology, Vol. 13

2021

  1. Efficacy and safety of intramuscular administration of allogeneic adipose tissue derived and expanded mesenchymal stromal cells in diabetic patients with critical limb ischemia with no possibility of revascularization: study protocol for a randomized controlled double-blind phase II clinical trial (The NOMA Trial)

    Trials, Vol. 22, Núm. 1

2020

  1. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study

    EClinicalMedicine, Vol. 25

  2. Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus (Frontiers in Immunology, (2019), 10, 10.3389/fimmu.2019.01151)

    Frontiers in Immunology

  3. Phase II multicenter randomized controlled clinical trial on the efficacy of intra-articular injection of autologous bone marrow mesenchymal stem cells with platelet rich plasma for the treatment of knee osteoarthritis

    Journal of Translational Medicine, Vol. 18, Núm. 1

2019

  1. Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus

    Frontiers in Immunology, Vol. 10, Núm. JUN

2018

  1. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: Long-term follow up of a multicenter randomized controlled clinical trial (phase I/II)

    Journal of Translational Medicine

2016

  1. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: Multicenter randomized controlled clinical trial (phase I/II)

    Journal of Translational Medicine, Vol. 14, Núm. 1

2014

  1. Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease

    Biology of Blood and Marrow Transplantation, Vol. 20, Núm. 10, pp. 1580-1585

2011

  1. Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: Results of a phase I/II clinical trial

    Haematologica, Vol. 96, Núm. 7, pp. 1072-1076